New meconium biomarkers of prenatal methamphetamine exposure increase identification of affected neonates

Clinical Chemistry

Volumn 56, Issue 5, 2010, Pages 856-860

  Gray, Teresa R ^a   Kelly, Tamsin ^a,b   LaGasse, Linda L ^c   Smith, Lynne M ^d   Derauf, Chris ^e   Grant, Penny ^f   Shah, Rizwan ^g   Arria, Amelia ^h   Haning, William ^e   Grotta, Sheri Della ^c   Strauss, Arthur ⁱ   Lester, Barry M ^c   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF CANBERRA   (Australia)

^c BROWN UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF HAWAII   (United States)

^f UNIVERSITY OF OKLAHOMA   (United States)

^g Blank Children's Hospital   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

ⁱ LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BIOLOGICAL MARKER; HYDROXYAMPHETAMINE; METHAMPHETAMINE; NOREPHEDRINE;

ARTICLE; CLINICAL RESEARCH; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MECONIUM; MOTHER; NEWBORN; PRENATAL EXPOSURE; SAMPLE; SCREENING; TANDEM MASS SPECTROMETRY; THIRD TRIMESTER PREGNANCY;

CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; HUMANS; INFANT, NEWBORN; MECONIUM; METHAMPHETAMINE; PREGNANCY; SUBSTANCE ABUSE DETECTION;

EID: 77951724917     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.139055     Document Type: Article

References (20)

1. Smith LM, LaGasse LL, Derauf C, Grant P, Shah R, Arria A, et al. The Infant Development, Environment, and Lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics 2006;118:1149-1156 (Pubitemid 46090058)
2. Derauf C, LaGasse LL, Smith LM, Grant P, Shah R, Arria A, et al. Demographic and psychosocial characteristics of mothers using methamphetamine during pregnancy: preliminary results of the Infant Development, Environment, and Lifestyle study (IDEAL). Am J Drug Alcohol Abuse 2007;33:281-289 (Pubitemid 46752589)
3. Gray TR, LaGasse LL, Smith LM, Derauf C, Grant P, Shah R, et al. Identification of prenatal amphetamines exposure by maternal interview and meconium toxicology in the Infant Development, Environment and Lifestyle (IDEAL) study. Ther Drug Monit 2009;31:769-775
4. Smith LM, Lagasse LL, Derauf C, Grant P, Shah R, Arria A, et al. Prenatal methamphetamine use and neonatal neurobehavioral outcome. Neurotoxicol Teratol 2008;30:20-28
5. Kacinko SL, Jones HE, Johnson RE, Choo RE, Huestis MA. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther 2008;84:604-612
6. Casanova OQ, Lombardero N, Behnke M, Eyler FD, Conlon M, Bertholf RL. Detection of cocaine exposure in the neonate. Analyses of urine, meconium, and amniotic fluid from mothers and infants exposed to cocaine. Arch Pathol Lab Med 1994;118:988-993
7. Steele BW, Bandstra ES, Wu NC, Hime GW, Hearn WL. m- Hydroxybenzoylecgonine: an important contributor to the immunoreactivity in assays for benzoylecgonine in meconium. J Anal Toxicol 1993;17:348-352
8. 9-THC. J Anal Toxicol 1998;22:329-335
9. Gray TR, Kelly T, LaGasse LL, Smith LM, Derauf C, Haning W, et al. Novel biomarkers of prenatal methamphetamine exposure in human meconium. Ther Drug Monit 2008;31:70-75
10. Arria AM, Derauf C, Lagasse LL, Grant P, Shah R, Smith L, et al. Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study. Matern Child Health J 2006;10:293-302.
11. Kelly T, Gray TR, Huestis MA. Development and validation of a liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for simultaneous analysis of 10 amphetamine-, methamphetamine- and 3,4-methylenediozymethamphetamine-related (MDMA) analytes in human meconium. J Chromatogr B Analyt Technol Biomed Life Sci 2008;867:194-204.
12. Gray TR, Shakleya DM, Huestis MA. A liquid chromatography tandem mass spectrometry method for the simultaneous quantification of 20 drugs of abuse and metabolites in human meconium. Anal Bioanal Chem 2009;393:1977-1990
13. Moore C, Lewis D, Leikin J. False-positive and false-negative rates in meconium drug testing. Clin Chem 1995;41:1614-1616 (Pubitemid 26280144)
14. Marin S, Keith L, Merrell M, McMillin G. Comparison of drugs of abuse detection in meconium by EMIT II and ELISA. J Anal Toxicol 2009;33:148-154
15. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM. Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol 1997;53:1605-1612 (Pubitemid 27356089)
16. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 2009;48:689-723.
17. Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol 2006;2:947-960
18. Cook CE, Jeffcoat AR, Hill JM, Pugh DE, Patetta PK, Sadler BM, et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetamine hydrochloride. Drug Metab Dispos 1993;21:717-723
19. Shima N, Kamata HT, Katagi M, Tsuchihashi H. Urinary excretion of the main metabolites of methamphetamine, including p-hydroxymethamphetaminesulfate and p-hydroxymethamphetamine-glucuronide, in humans and rats. Xenobiotica 2006;36:259-267
20. Marin JJG, Macias RIR, Briz O, Perez M, Blazquez A, Arrese M, Serrano M. Molecular bases of the fetal liver-placenta-maternal liver excretory pathway for cholephilic compounds. Liver Int 2008;28:435-454 (Pubitemid 351411130)